fda warning letters glp-1 compounding september 26 2025 NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP -1 Weight Loss Drugs CDER Warning Letters Jump 50%

Contact your GP if you experience persistent gastrointestinal symptoms, unusual bleeding or bruising (particularly if taking anticoagulants), seizures, or any other concerning symptoms after starting supplementation

No - see contraindications below

Dietary Considerations The appetite suppression from Semaglutide naturally reduces caloric intake, but what you eat matters as much as how much

Theobromine Another compound that Unimate praises is the theobromine content in yerba mate

Sermorelin a GHRH fragment researched for stimulating endogenous GH production

Furthermore, a prespecified subgroup analysis of HF individuals from the SELECT trial evaluating the effects of semaglutide on cardiovascular outcomes in people with overweight or obesity, which included 2,273 HFpEF and 1,347 HFrEF patients, showed that the therapy was associated with a reduction in the HF composite outcome (cardiovascular death or HF hospitalisation/emergency visit) across LVEF, suggesting that GLP-1 RAs may improve outcomes at least in obese HF patients regardless of diabetes status